SAN CARLOS, Calif., April 25, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced today that Kimberly Martin, MD, FRCSC, FCCMG, FACOG, FACMG has assumed a new role as the new senior global medical director of Natera's Women's Health franchise. She previously served as the medical director for Reproductive Testing at Natera.
Dr. Martin is a nationally recognized expert clinician in the field of interventional genetics with more than 20 years of prenatal diagnosis, ultrasound, and genetic counseling experience practicing in both academic and community-based healthcare settings. She has participated in the training of medical students, residents and fellows in maternal-fetal medicine and has lectured extensively about reproductive genetics.
She is particularly interested in improving the education of providers and patients' genetic health literacy and the medical ethics surrounding the genetics field.
"Dr. Martin's experience and expertise in the field of medical genetics – specifically prenatal diagnosis, genetics counseling, and the management of fetal birth defects – enables her to lead Natera's clinical strategy and generate awareness around the evidence-based medical work that we're doing as a leader and innovator in the field of prenatal genetic testing," Matthew Rabinowitz, Ph.D. and Chief Executive Officer of Natera, said. "Her relationship building and communication skills, deep understanding of prenatal clinical research and close relationships with our regulatory and corporate development teams adds a high caliber of talent and depth to our current leadership team. This will be extremely valuable as we continue to build upon the Natera brand and expand our product portfolio in the Women's Health space."
Dr. Martin received her medical degree from McGill University in Montreal, Canada. She completed her residency in Obstetrics and Gynecology at the University of Western Ontario in London, Canada and a fellowship in Clinical Genetics at the University of British Columbia in Vancouver, Canada. She is board certified in both Obstetrics and Gynecology and Clinical Genetics in Canada and the United States.
"Natera has an innovative reproductive health portfolio, with genetic technology that can improve a pregnant woman's prenatal testing options in a profound way," Dr. Kim Martin said. "I'm looking forward to starting this new chapter in my professional career and partnering with Natera's more than 40 board-certified genetic counselors – one of the largest teams in the industry – to further develop Natera's clinical strategy."
Editor's Note: Photograph available on request.
Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. Tests include the Spectrum® pre-implantation genetic test for embryo selection during IVF; the Anora® miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama® non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration. For more information, visit http://www.natera.com/ and connect on Twitter and Facebook.
This release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. Any forward-looking statements contained in this press release are based upon Natera's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release. Subsequent events may cause these expectations to change, and Natera disclaims any obligation to update the forward-looking statements for any reason after the date of this press release. These forward-looking statements are subject to a number of known and unknown risks and uncertainties that may cause actual results to differ materially, including uncertainty in the development and commercialization of Natera's planned future cancer products or other new products or if the results of its clinical studies do not support the use of its tests, or cannot be replicated in later studies required for regulatory approvals or clearances. Additional risks and uncertainties are discussed in greater detail in the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Natera's Form 10-K for the year ended December 31, 2015. Further information on potential risks that could affect actual results will be included in other filings Natera makes with the SEC from time to time. These documents are available for free on the company's website at www.natera.com under the Investor Relations section, and on the SEC's website at www.sec.gov.
Mike Brophy, Investor Relations, 650-249-9091 x1471
Laura Zobkiw, Corporate and Media Relations, 650-249-1649 x1649
SOURCE Natera, Inc.